Atkinson M H, Buchanan W W, Fitzgerald A A, Lussier A, Tannenbaum H H
Rheumatic Disease Unit, Calgary General Hospital, University of Calgary, Alberta, Canada.
Curr Med Res Opin. 1990;12(2):76-85. doi: 10.1185/03007999009110474.
A 6-week double-blind, parallel controlled, randomized study was carried out to compare the efficacy and tolerability of 100 mg flurbiprofen twice daily with 375 mg naproxen twice daily in patients with rheumatoid arthritis. One hundred and six patients from five centres were evaluable; 52 from the flurbiprofen group and 54 from the naproxen group. Evaluation of the primary efficacy parameters demonstrated no difference in efficacy between the treatment groups. In general, the results of evaluation of the secondary efficacy parameters also supported similar improvement for both treatment groups. The overall incidence of adverse clinical/laboratory experiences was similar between the treatment groups. Five patients, 3 flurbiprofen and 2 naproxen-treated, discontinued the study, all because of gastro-intestinal intolerance.
进行了一项为期6周的双盲、平行对照、随机研究，以比较类风湿性关节炎患者每日两次服用100毫克氟比洛芬与每日两次服用375毫克萘普生的疗效和耐受性。来自五个中心的106名患者可进行评估；氟比洛芬组52名，萘普生组54名。主要疗效参数评估显示治疗组之间疗效无差异。总体而言，次要疗效参数的评估结果也支持两个治疗组有相似的改善。治疗组之间不良临床/实验室事件的总发生率相似。5名患者（3名接受氟比洛芬治疗，2名接受萘普生治疗）停止了研究，均因胃肠道不耐受。
